Literature DB >> 22110398

Role of inflammation in benign prostatic hyperplasia.

Bilal Chughtai1, Richard Lee, Alexis Te, Steven Kaplan.   

Abstract

Inflammation of the prostate may represent a mechanism for hyperplastic changes to occur in the prostate. There are a variety of growth factors and cytokines that may lead to a proinflammatory process within the prostate. There are several proposed mechanisms that lead to both the intrinsic and extrinsic basis of inflammation. Prostatic inflammation may represent an important factor in influencing prostatic growth and progression of symptoms. This article reviews the recent literature on inflammation leading to chronic prostatic diseases, such as benign prostatic hyperplasia.

Entities:  

Keywords:  Benign prostatic hyperplasia; Inflammation; Prostatic cytokines; Prostatitis; Vitamin D

Year:  2011        PMID: 22110398      PMCID: PMC3221555     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  18 in total

Review 1.  Chronic prostatitis-an infectious disease?

Authors:  K G Naber; W Weidner
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

Review 2.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

3.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.

Authors:  R B Nadler; P A Humphrey; D S Smith; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

4.  Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.

Authors:  Siavash Falahatkar; Gholamreza Mokhtari; Farshid Pourreza; Seyed Alaeddin Asgari; Alireza Noshad Kamran
Journal:  Urology       Date:  2008-08-09       Impact factor: 2.649

5.  Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.

Authors:  Georg E Steiner; Martin E Newman; Doris Paikl; Ursula Stix; Nima Memaran-Dagda; Chung Lee; Michael J Marberger
Journal:  Prostate       Date:  2003-08-01       Impact factor: 4.104

6.  BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.

Authors:  R Vela Navarrete; J V Garcia Cardoso; A Barat; F Manzarbeitia; A López Farré
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

7.  Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.

Authors:  Wanzhong Wang; Anders Bergh; Jan-Erik Damber
Journal:  Prostate       Date:  2004-09-15       Impact factor: 4.104

8.  The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.

Authors:  Giuseppe Penna; Benedetta Fibbi; Susana Amuchastegui; Elisa Corsiero; Gilles Laverny; Enrico Silvestrini; Aravinda Chavalmane; Annamaria Morelli; Erica Sarchielli; Gabriella Barbara Vannelli; Mauro Gacci; Enrico Colli; Mario Maggi; Luciano Adorini
Journal:  Prostate       Date:  2009-04-01       Impact factor: 4.104

9.  Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.

Authors:  Grégoire Robert; Aurélien Descazeaud; Nathalie Nicolaïew; Stéphane Terry; Nanor Sirab; Francis Vacherot; Pascale Maillé; Yves Allory; Alexandre de la Taille
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

10.  Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.

Authors:  J Curtis Nickel; Claus G Roehrborn; Michael P O'leary; David G Bostwick; Matthew C Somerville; Roger S Rittmaster
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450

View more
  58 in total

1.  Effects of low-frequency ultrasound combined with microbubbles on benign prostate hyperplasia.

Authors:  Shao-Ling Yang; Ke-Qiang Tang; Wen-Kun Bai; E Shen; Yi-Wen Zhao; Yan-Duan Lin; Shu-Liang Nan; Hu Bing
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

Review 2.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

3.  Bacteriological Profile of Isolates From Urine Samples in Patients of Benign Prostatic Hyperplasia and or Prostatitis Showing Lower Urinary Tract Symptoms.

Authors:  Prem Prakash Mishra; Ved Prakash; Kashmir Singh; H Mog; Sumit Agarwal
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 4.  The Emerging Role of Inflammasomes as Central Mediators in Inflammatory Bladder Pathology.

Authors:  Brian M Inouye; Francis M Hughes; Stephanie J Sexton; J Todd Purves
Journal:  Curr Urol       Date:  2017-12-30

Review 5.  Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia.

Authors:  Youngjoo Kwon
Journal:  Food Sci Biotechnol       Date:  2019-04-17       Impact factor: 2.391

6.  DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.

Authors:  Rongbin Ge; Zongwei Wang; Seth K Bechis; Alexander G Otsetov; Shengyu Hua; Shulin Wu; Chin-Lee Wu; Shahin Tabatabaei; Aria F Olumi
Journal:  Am J Pathol       Date:  2015-02-17       Impact factor: 4.307

7.  A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes.

Authors:  Debika Biswal Shinohara; Ajay M Vaghasia; Shu-Han Yu; Tim N Mak; Holger Brüggemann; William G Nelson; Angelo M De Marzo; Srinivasan Yegnasubramanian; Karen S Sfanos
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

Review 8.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

Review 9.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

10.  Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia.

Authors:  Shao-ling Yang; Ke-qiang Tang; Wen-kun Bai; Yi-Wen Zhao; E Shen; Jun-jia Tao; Bing Hu
Journal:  J Endourol       Date:  2013-08       Impact factor: 2.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.